SG11202012595PA - Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain - Google Patents

Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain

Info

Publication number
SG11202012595PA
SG11202012595PA SG11202012595PA SG11202012595PA SG11202012595PA SG 11202012595P A SG11202012595P A SG 11202012595PA SG 11202012595P A SG11202012595P A SG 11202012595PA SG 11202012595P A SG11202012595P A SG 11202012595PA SG 11202012595P A SG11202012595P A SG 11202012595PA
Authority
SG
Singapore
Prior art keywords
propenone
ylamino
pyrimidin
piperidin
phenoxy
Prior art date
Application number
SG11202012595PA
Other languages
English (en)
Inventor
Michael Lange
Clemens Kuehn
Tobias Schlueter
Werner Mederski
David Maillard
Edoardo Burini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11202012595PA publication Critical patent/SG11202012595PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202012595PA 2018-06-19 2019-06-17 Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain SG11202012595PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862686797P 2018-06-19 2018-06-19
PCT/EP2019/065815 WO2019243223A1 (en) 2018-06-19 2019-06-17 Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain

Publications (1)

Publication Number Publication Date
SG11202012595PA true SG11202012595PA (en) 2021-01-28

Family

ID=67003464

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012595PA SG11202012595PA (en) 2018-06-19 2019-06-17 Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain

Country Status (12)

Country Link
US (2) US11878967B2 (de)
EP (1) EP3810590A1 (de)
JP (1) JP2021527685A (de)
KR (1) KR20210022674A (de)
CN (1) CN112313214A (de)
BR (1) BR112020025881A2 (de)
CA (1) CA3104191A1 (de)
CL (1) CL2020003272A1 (de)
IL (1) IL279485A (de)
MX (1) MX2020013321A (de)
SG (1) SG11202012595PA (de)
WO (1) WO2019243223A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240024314A1 (en) * 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
MX2022008490A (es) * 2020-01-08 2022-10-13 Telios Pharma Inc Metodos de tratamiento de la esplenomegalia.
US20230295509A1 (en) 2020-06-10 2023-09-21 Merck Patent Gmbh Steerable antenna and method for heating and/or tempering of a steerable antenna
CN117986236A (zh) * 2022-11-07 2024-05-07 天津征程医药科技有限公司 氘代的嘧啶衍生物以及包含该化合物的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201801668WA (en) 2011-06-10 2018-03-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
SG11201408067YA (en) 2012-06-04 2015-01-29 Pharmacyclics Inc Crystalline forms of a bruton's tyrosine kinase inhibitor
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法
WO2016139588A1 (en) * 2015-03-03 2016-09-09 Dr. Reddy's Laboratories Limited Polymorphs of ibrutinib
CN107873029B (zh) * 2015-04-02 2020-09-01 拉蒂奥法姆有限责任公司 依鲁替尼与羧酸的共晶体
EP4014977A1 (de) * 2015-11-04 2022-06-22 Merck Patent GmbH Pyrimidin-verbindungen mit btk-hemmender wirkung zur verwendung bei der behandlung von krebs
PT3377484T (pt) 2015-11-17 2023-12-14 Merck Patent Gmbh Métodos para tratamento de esclerose múltipla utilizando compostos de pirimidina e piridina com atividade inibidora de btk
US10464923B2 (en) * 2017-02-27 2019-11-05 Merck Patent Gmbh Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone

Also Published As

Publication number Publication date
KR20210022674A (ko) 2021-03-03
JP2021527685A (ja) 2021-10-14
WO2019243223A1 (en) 2019-12-26
AU2019289628A1 (en) 2021-02-04
US20210261525A1 (en) 2021-08-26
EP3810590A1 (de) 2021-04-28
BR112020025881A2 (pt) 2021-03-23
MX2020013321A (es) 2021-02-22
IL279485A (en) 2021-01-31
US20240132472A1 (en) 2024-04-25
CL2020003272A1 (es) 2021-05-07
CN112313214A (zh) 2021-02-02
US11878967B2 (en) 2024-01-23
CA3104191A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
ZA201906361B (en) Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone
SG11202012595PA (en) Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
MX2017014108A (es) Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-ilox i) metilo) ciclopropanamina, su forma cristalina y sus sales.
WO2016105525A3 (en) Novel pyrimidines as egfr inhibitors and methods of treating disorders
MY195183A (en) Heterocyclic Amides as Kinase Inhibitors
EP3802466A4 (de) Salze von diaminoacetalen und diaminoketalen sowie ihre herstellung und ihre umwandlung in diaminoacetale und diaminoketale
PL3464276T3 (pl) Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu
SG11201707899SA (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
MX2021013970A (es) Formas cristalinas de n-[4-(clorodifluorometoxi)fenil]-6-[(3r)-3-h idroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida.
IL273974A (en) Amine-Disubstituted Heterocyclic Compounds as EHMT2 Inhibitors, Their Salts, and Method for Their Synthesis
HK1204788A1 (en) Method of producing 4-[5-(pyridin-4-yl)-1h-1,2,4-triazole-3- yl]pyridin-2-carbonitrile, and intermediary thereof 4-[5-(-4-)-1h-124--3-]-2-
HK1245268A1 (zh) 含氮雜環化合物的製造方法及其中間體
IL257463A (en) Novel crystalline form of 3-(6-(1-(2, 2-difluorobenzo [d] [1, 3] dioxole -5-yl) cyclopropanecarboxamido)-3-methylpyridine-2-yl) benzoic acid and process of preparation thereof
MX2017011330A (es) Proceso quimico para preparar derivados de pirimidina y sus intermediarios.
ZA201907272B (en) N-(4-pyridyl)nicotinamide compound or salt thereof
NZ742785A (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
GB2534913B (en) System, method, and program for storing and controlling access to data representing personal behaviour
IL253717A0 (en) Crystalline form of s-(4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl)6a,9a-difluoro-17a,-(furan-2-yl)carbonyloxy-11b-hydroxy-16a-methy1-3 -oxoandrosta-1,4-diene-17b-carbothioate
EP3345898A4 (de) Kristalle von 5-cyclopropyl-2-((1-(3-fluorbenzyl) ) -1 h-indol-5-yl) amino) nicotinsäure
EA201991977A1 (ru) Новые кристаллические формы 1-(4-{[6-амино-5-(4-феноксифенил)пиримидин-4-иламино]метил}пиперидин-1-ил)пропенона
FR3019715B1 (fr) Composition fertilisante et biostimulante contenant des fructo-oligosaccharides, procede d'application et utilisations
GB201512158D0 (en) Manufacture Process of Biocomposite Panelsand Packaging by Use of Protein-Con taining Non-Wood Fibrous Biomass